2 Indian States Go Big On Drug Ivermectin Despite WHO Advice

0

The move by Goa and Uttarakhand, come despite the World Health Organization and others warning against such measures.

2 Indian States Go Big On Drug Ivermectin Despite WHO Advice

Uttarakhand announced plans on Wednesday to distribute the tablets to any person over the age of two.



Bengaluru:

At least two Indian states have said they plan to dose their populations with the anti-parasitic drug ivermectin to protect against severe COVID-19 infections as their hospitals are overrun with patients in critical condition.

The move by Goa and Uttarakhand, come despite the World Health Organization and others warning against such measures.

“The current evidence on the use of ivermectin to treat COVID-19 patients is inconclusive,” WHO said in a statement in late March. “Until more data is available, WHO recommends that the drug only be used within clinical trials.”

Merck, a manufacturer of the drug, has also said available data does not support using the drug as a COVID-19 treatment.

“We do not have enough data to support its use,” said Anita Mathew, an infectious diseases expert in Mumbai.

Goa, a major tourist haven, said earlier this week it plans to give ivermectin to all those older than 18, while Uttarakhand announced plans on Wednesday to distribute the tablets to any person over the age of two, except for pregnant and lactating women.

“An expert medical panel has recommended this” Uttarakhand’s Chief Secretary Om Prakash told Reuters. “We are waiting for supplies to come in. Once they do we will distribute this drug.”

Uttarakhand in March and April played host to the Kumbh Mela, a weeks-long Hindu gathering that attracted millions of devotees from across the country. Images of the gathering showed scant evidence of any mask wearing or social distancing as throngs of people congregated for a holy dip in the river Ganges.

The state, ruled by Prime Minister Narendra Modi’s Bharatiya Janata Party, has since early April seen its COVID-19 cases surge from under 300 a day to above 7,000 a day and the death toll has also risen sharply.

PM Modi and other political leaders in India have faced sharp criticism for failing to stop big religious and political gatherings in many states, despite evidence from mid-February onward that India’s case count was rising.

Despite India’s overwhelming surge in cases, PM Modi has shied away from imposing a nationwide lockdown fearing the economic fallout and has left it to state governments, which experts say have acted too late.

Uttarakhand currently has coronavirus-related social restrictions, including curbs on interstate travel.

Goa, which is also ruled by PM Modi’s BJP, remains open to tourists and only imposed an extended 15-day lockdown this week, despite data showing more than one in three patients were testing positive for COVID-19 since mid-April. The state is reporting the highest positivity rates in the country.

Goa Health Minister Vishwajit Rane said an expert panel based in Europe had found the drug ivermectin reduced the time to recovery and risk of death, but regulators such as WHO and the U.S. Food and Drug Administration say there is little evidence of this.

The state-run Indian Council of Medical Research recommends doctors could use the drug for mild COVID-19 patients, but warns this is based on “low certainty of evidence”.

Mr Rane did not respond to a Reuters request for comment.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

All the data shown above will be stored by www.rajpostexam.com on https://www.rajpostexam.com/. At any point of time, you can contact us and select the data you wish to anonymise or delete so it cannot be linked to your email address any longer. When your data is anonymised or deleted, you will receive an email confirmation. We also use cookies and/or similar technologies to analyse customer behaviour, administer the website, track users' movements, and to collect information about users. This is done in order to personalise and enhance your experience with us. Click here to read our Cookie Policy.